ASX:CSL 16 February 2026 - 8 June 2026

CSL stock eyes new test as Sanofi enters picture after tough year
··

CSL stock eyes new test as Sanofi enters picture after tough year

CSL Ltd. is back in focus for Thursday’s Australian session, as Sanofi put pledges to EU regulators about its actions toward CSL Seqirus’s Fluad flu shot. Investors are watching the latest on the vaccine development. The stock finished Wednesday up 0.27% at A$124.30. The S&P/ASX 200, which tracks big listed names and is a key local market benchmark for institutions, slipped 0.21% to 8,785.10.
July 8, 2026
CSL jumps 5.75% before ASX to restart after King’s Birthday break
·

CSL jumps 5.75% before ASX to restart after King’s Birthday break

CSL Limited will resume trading on the ASX on Tuesday, with Friday’s jump to A$97.91 the most recent close. Shares climbed A$5.32, or 5.75%, in that session. The market was closed Monday for the King’s Birthday holiday—ASX listed June 8 as a non-settlement day. CSL’s bounce stood out as the S&P/ASX 200 dropped 0.7% to 8,625.10 on Friday and lost 1.2% this week. Banks and miners drove most of the losses for Australia’s main large-cap index.
June 8, 2026
ASX Opens as Banks, Miners and Oil on Radar for Next Moves
·········

ASX Opens as Banks, Miners and Oil on Radar for Next Moves

ASX eyes muted open as miners, banks slip before long weekend Australian stocks are expected to open cautiously Tuesday, with S&P/ASX 200 futures held down by Friday’s 0.7% drop to 8,625.10 and weak trading in banks and miners. The ASX cash market didn’t trade on Monday because of the King’s Birthday holiday. Regular trading is set to start around 10 a.m. Sydney time. ASX traders come back after missing Monday’s overseas action. U.S. stocks climbed Monday, led by a rebound in chip stocks after last week’s drop. Some signs that Middle East tensions eased also helped, leaving Australians returning to a stronger offshore lead than they had before the market closed on Friday.
June 8, 2026
Cochlear Jumps; Eyes on Tuesday ASX Reopen After Pop
··

Cochlear Jumps; Eyes on Tuesday ASX Reopen After Pop

Cochlear Limited enters the holiday week at A$100.45, Friday’s last price, after shares jumped A$5.35, or 5.63%. It was one of the stronger S&P/ASX 200 performers while the index dropped 0.7% to 8,625.1. CSL, in the broader ASX healthcare group, finished up 5.75%. ASX cash trading is shut Monday for the King’s Birthday holiday on June 8. The next session opens Tuesday, giving investors a first look at whether Friday’s lift was more than just short-covering or bargain hunting.
June 7, 2026
CSL Shares Up 5.75%, What Comes Next May Be Tougher
·

CSL Shares Up 5.75%, What Comes Next May Be Tougher

CSL Limited moves into the holiday week with Friday’s rally still fresh. Shares finished at A$97.91, up 5.75%, as investors picked up beaten-down health care stocks ahead of the break. CSL’s rally is in focus now after May’s sharp downgrade, which had investors debating whether CSL’s earnings issues are passing or of its own making. The ASX cash market is shut Monday for King’s Birthday, leaving Friday’s close as the last tradeable price.
June 7, 2026
ASX Faces Volatile Tuesday Reopen After Long Weekend as Banks and Miners Watch Wall Street
········

ASX Faces Volatile Tuesday Reopen After Long Weekend as Banks and Miners Watch Wall Street

Australian stocks ended lower ahead of the long weekend, as the S&P/ASX 200 dropped for the week—its first weekly decline in three weeks. Banks and miners weighed the index down on Friday. The index gave up 61 points, or 0.7%, settling at 8,625.10. That put losses for the week at 1.2%. Share trading on the ASX stays closed Monday for the King’s Birthday holiday. The next local session is set for Tuesday.
June 6, 2026
CSL Rises, $5 Billion Cloud Remains
····

CSL Rises, $5 Billion Cloud Remains

CSL Ltd shares climbed on Tuesday, clawing back some of last week's losses. The stock stayed under A$100 as investors watched for more evidence that the recent earnings reset has stabilized the biotech firm. The ASX cash market wasn’t open at press time. Sydney’s regular session is from 09:59:45 to 16:00, so CSL traders are waiting for action in Wednesday’s opening auction and the first trades.
May 19, 2026
CSL shares fall under A$100 with market wary on turnaround
····

CSL shares fall under A$100 with market wary on turnaround

CSL Ltd shares dropped again Monday, ending at A$96.22, down A$1.74 or 1.78%. Investors continued to exit after last week’s profit downgrade and news of planned impairments. The shares moved between A$95.87 and A$98.38 on the day. CSL didn't just slide with the market on Monday. The S&P/ASX 200 dropped 1.45% to 8,505.3, but CSL ended the day down 19.74% from the A$119.88 price it posted at its May 11 market update.
May 18, 2026
CSL shares under pressure as traders eye critical week
····

CSL shares under pressure as traders eye critical week

CSL Ltd starts Monday as traders weigh last week’s 18% fall. The drop followed a profit warning and a non-cash impairment of about $5 billion, a write-down that reduces asset values but has no instant cash impact. The ASX cash market is still shut after the weekend, with trading set to start around 09:59:45 Sydney time. CSL's slide is weighing on the market now, where it used to be a safe spot. CSL ended Friday at A$97.96, up 0.72% for the day, but down 18.3% across five sessions. The S&P/ASX 200 closed at 8,630.8, dropping 0.11% on Friday.
May 17, 2026
CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock
····

CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock

CSL Limited shares slipped again on Thursday, deepening the week’s losses for the Australian biotech after investors were rattled by a profit warning and upcoming writedowns. The stock wrapped up at A$97.26, off 1.55%, based on delayed quotes after the bell. CSL’s stock is still stuck around where it was in early 2017 — a level not seen in years. Monday’s 90-day strategic review, led by interim CEO Gordon Naylor, only deepened the slump. Reuters said shares slid as much as 17.8% that day, touching A$98.590, a low not reached since Jan. 19, 2017.
May 14, 2026
CSL Limited’s $5 Billion Write-Down Leaves One Big Question: Is the Turnaround Still Alive?
····

CSL Limited’s $5 Billion Write-Down Leaves One Big Question: Is the Turnaround Still Alive?

CSL Limited managed to halt its slide Wednesday, clawing back some ground after a steep drop. The company rattled investors this week with news of roughly US$5 billion in new non-cash impairments and a lowered fiscal 2026 forecast, sharply altering sentiment around the Australian biotech. Shares finished the day at A$98.79, inching up 0.24%, though the price remains a bruising 58.8% lower over the past year, according to market data. It’s not just a single disappointing trading update at this point. CSL — long seen by Australian investors as a reliable healthcare name — is scrambling to shore up trust, but there’s still no permanent CEO in place. The overhang from the Vifor acquisition back in 2022 continues to drag
May 13, 2026
UK & AU Stock Market Today: Live Updates 13.05.2026
··

UK & AU Stock Market Today: Live Updates 13.05.2026

LIVEMarkets rolling coverageStarted: May 13, 2026, 12:00 AM EDTUpdated: May 13, 2026, 11:58 PM EDT Federal Court Rules Coles Misled Shoppers with 'Down Down' Discounts May 13, 2026, 11:58 PM EDT. The Federal Court ruled that Australian supermarket giant Coles misled customers by promoting fake "Down Down" discounts on everyday groceries. Justice Michael O'Bryan found Coles' tactic of showing inflated "was" prices for short periods before applying "discounted" prices was deceptive. The Australian Competition and Consumer Commission (ACCC) sued Coles over the practice between 2021 and 2023, arguing the promotional campaigns disguised actual price increases amid inflation. Coles argued these
May 13, 2026
CSL Limited Buyback Tops A$1 Billion After Stock Hits 2017 Low
····

CSL Limited Buyback Tops A$1 Billion After Stock Hits 2017 Low

CSL Limited repurchased 110,004 shares on April 30, according to a May 1 filing with the ASX. That brings the total bought back under its on-market program to 6.35 million shares, with around A$1.06 billion paid or committed so far. The buyback, which is capped at US$750 million, is scheduled to run through June 30. The filing comes as CSL faces a tough stretch. Reuters noted last week that shares hit their lowest point since late August 2017 after the U.S. military dropped its flu vaccine mandate. Marc Jocum, senior product and investment strategist at GlobalXETFs, called the Pentagon’s move a hit “at the worst possible time.” But for Vantage Markets analyst Hebe Chen, “the real issue runs deeper” than
May 1, 2026
Australia Stock Market This Week: ASX 200’s Worst Week Since March as Oil Shock, Fortescue Selloff Bite
·········

Australia Stock Market This Week: ASX 200’s Worst Week Since March as Oil Shock, Fortescue Selloff Bite

The S&P/ASX 200 ended Friday at 8,786.50, capping a 1.8% drop for the week—its steepest decline since mid-March—as the market struggled with Middle East jitters, a selloff in healthcare, and sliding miners. On the day, the benchmark edged down 6.9 points, or 0.08%. Miners shed 1.1%. Banks, though, eked out a late 0.3% gain. Timing is key here: the selloff landed just as investors juggled two themes—potential diplomacy efforts in the Middle East and the threat that stubbornly high oil prices could keep inflation burning. Higher crude bumps up fuel costs, can bite into company margins, and tends to firm up expectations for where interest rates might head next. The ASX’s RBA Rate Indicator shows how the market prices potential
April 25, 2026
CSL Limited Stock Price Drops as HEMGENIX Shortage Overshadows Fresh Buyback
····

CSL Limited Stock Price Drops as HEMGENIX Shortage Overshadows Fresh Buyback

CSL Ltd repurchased 74,167 more shares on March 18, yet the stock ended the session 2.23% lower at A$138.00. Investors weighed a new alert: supplies of its hemophilia B gene therapy HEMGENIX are temporarily short worldwide. Just five weeks ago, CSL jolted the market with an 81% plunge in first-half profit, hefty write-downs, and the sudden exit of CEO Paul McKenzie—a combination that knocked shares down to their lowest level in eight years. The stock is now sitting at A$138.00, nearly halved from its 12-month peak of A$272.00, down about 49%.
March 19, 2026
CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares
····

CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares

CSL Ltd's vaccine business, Seqirus, has locked in a Canadian government contract to deliver up to 15 million pandemic influenza vaccine doses from its Victoria site if a flu pandemic is declared by the World Health Organization. This marks the first supply deal for CSL’s new Tullamarine facility outside the Asia-Pacific region, the company noted. Timing counts here. CSL badly needed some positive news, coming off an eight-year share price low last month after the biotech logged an 81% plunge in half-year profit and unexpectedly swapped out its chief executive. For Seqirus, the deal lands as a rare export win not long after CSL abandoned plans to spin off the vaccines unit, following a decline in U.S. flu vaccine uptake.
March 6, 2026
CSL shares rebound after neffy nasal spray approval as buyback rolls on
····

CSL shares rebound after neffy nasal spray approval as buyback rolls on

Sydney, February 16, 2026, 17:01 AEDT — The session has ended. CSL Ltd picked up 1.4% by Monday’s close, recouping a slice of last week’s drop. The move followed news that its Seqirus arm secured Australian approval for the neffy adrenaline nasal spray, alongside a fresh update on the company’s share buyback. Shares wrapped up at A$152.17, though that’s still roughly 15.6% below where they stood five sessions ago.
February 16, 2026
1 2